Stockscreener 앱 받기
1.66
4.06%
0.06
시간 외 거래:
1.67
0.01
+0.60%
Lineage Cell Therapeutics Inc 주식(LCTX)의 최신 뉴스
Cell Therapy Manufacturing Market Forecast Through 2032 - openPR.com
Lineage Cell Therapeutics: Progress Amid Financial Challenges - MSN
EBIT per share of Lineage Cell Therapeutics, Inc. – DUS:BT3 - TradingView — Track All Markets
Q3 2025 Lineage Cell Therapeutics Inc Earnings Call Transcript - GuruFocus
Is Lineage Cell Therapeutics Inc. stock supported by innovation pipelineJuly 2025 Chart Watch & Safe Capital Allocation Plans - Улправда
Is Lineage Cell Therapeutics Inc. stock trading at a premium valuation2025 Pullback Review & High Yield Equity Trading Tips - Улправда
Aug Wrap: Can Lineage Cell Therapeutics Inc. stock surprise with earnings upsideWeekly Gains Report & Daily Momentum Trading Reports - Улправда
Lineage Cell Therapeutics (LCTX) officer reports RSU vesting and tax share withholding - Stock Titan
Can Lineage Cell Therapeutics Inc. stock surprise with earnings upside2025 Dividend Review & Real-Time Buy Signal Notifications - Улправда
Will Lineage Cell Therapeutics Inc. stock outperform foreign stocksPortfolio Value Report & Stepwise Entry/Exit Trade Alerts - DonanımHaber
Why Lineage Cell Therapeutics Inc. stock is a must watch in 2025Market Activity Recap & Verified Stock Trade Ideas - DonanımHaber
Buybacks Report: How rising interest rates impact Lineage Cell Therapeutics Inc. stockTreasury Yields & Daily Chart Pattern Signals - Улправда
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading 4.7% HigherShould You Buy? - MarketBeat
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading 4.7% Higher – Should You Buy? - Defense World
Aug Shorts: Can Lineage Cell Therapeutics Inc stock withstand sector downturnsPortfolio Gains Report & AI Powered Trade Plan Recommendations - moha.gov.vn
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy - PR Newswire
New Horizons in Cancer Stem Cells Market Exclusive Report with - openPR.com
You might want to take a look at Lineage Cell Therapeutics Inc (LCTX) now - setenews.com
Lineage Cell Therapeutics Q3 2025 Earnings Preview - MSN
Model VAC2Immuno-Oncology for Non-Small Cell Lung Cancer (NSCLC) - Environmental XPRT
How Lineage Cell Therapeutics Inc. stock valuation compares with sector2025 Historical Comparison & Smart Investment Allocation Tips - Newser
What insider trading reveals about Lineage Cell Therapeutics Inc. stockSell Signal & Daily Growth Stock Tips - Newser
Is Lineage Cell Therapeutics Inc. stock a smart buy before Fed meetingJuly 2025 Short Interest & AI Optimized Trading Strategy Guides - Newser
How Lineage Cell Therapeutics Inc. stock performs during market turbulence2025 Top Decliners & Safe Swing Trade Setups - Newser
How currency fluctuations impact Lineage Cell Therapeutics Inc. stockPortfolio Value Summary & Accurate Intraday Trade Tips - Newser
Is Lineage Cell Therapeutics Inc. stock safe for risk averse investorsCEO Change & Daily Stock Trend Reports - Newser
Is Lineage Cell Therapeutics Inc. stock attractive for growth ETFsPortfolio Gains Summary & Free Expert Verified Stock Movement Alerts - Newser
Is Lineage Cell Therapeutics Inc. stock cheap by valuation metricsJuly 2025 Review & Entry Point Confirmation Alerts - Newser
Is Lineage Cell Therapeutics Inc. stock expanding market penetrationMarket Growth Report & Technical Entry and Exit Alerts - Newser
Will Lineage Cell Therapeutics Inc. stock beat international competitionJuly 2025 Action & Precise Swing Trade Entry Alerts - Newser
LCTX SEC FilingsLineage Cell The 10-K, 10-Q, 8-K Forms - Stock Titan
An analyst sees good growth prospects for Lineage Cell Therapeutics Inc (LCTX) - setenews.com
Is Lineage Cell Therapeutics Inc. stock a buy on weaknessTreasury Yields & Long-Term Growth Plans - Newser
Can Lineage Cell Therapeutics Inc. stock weather global recession2025 Winners & Losers & Technical Pattern Based Buy Signals - Newser
Lineage Cell Therapeutics withdraws CIRM grant application, plans resubmission By Investing.com - Investing.com Australia
Lineage Therap Withdraws CIRM Grant Application - TipRanks
Lineage Cell Therapeutics Inc withdrew CIRM grant application filed in June 2025SEC filing - marketscreener.com
Lineage Cell Therapeutics withdraws CIRM grant application, plans resubmission - Investing.com
Lineage Cell Therapeutics Withdraws CIRM Grant Application - TradingView — Track All Markets
Lineage Cell Therapeutics (LCTX) pulls CIRM CLIN2 grant application, plans OPC1 resubmission - Stock Titan
Published on: 2025-12-10 00:53:07 - earlytimes.in
Does Tuni Textile Mills Limited Have Competitive Moats for LongTerm GrowthDividend Yield Trends & Superior Wealth Strategies - earlytimes.in
Can Shri Jagdamba Polymers Limited Deliver Stable Cash Flow in Market DownturnsRisk-Reward Ratio Analysis & Fast Profit Portfolio Plans - earlytimes.in
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from D. Boral Capital - Defense World
Lineage Cell Therapeutics' (LCTX) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Lineage Cell says first OpRegen development milestone under Roche pact achieved - MSN
This trade activity should not be overlooked: Lineage Cell Therapeutics Inc (LCTX) - Setenews
D. Boral Capital Maintains Lineage Cell Therapeutics (LCTX) Buy Recommendation - Nasdaq
Lineage Cell Therapeutics explores future of dry AMD treatment - Traders Union
LCTX: D. Boral Capital Maintains 'Buy' Rating with $2.00 Price T - GuruFocus
HC Wainwright & Co. Maintains Lineage Cell Therapeutics (LCTX) Buy Recommendation - Nasdaq
HC Wainwright & Co. Maintains Buy Rating for LCTX with $9 Target - GuruFocus
0.84%
0.01%
자본화:
|
볼륨(24시간):